Search
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalLutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. … In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated a lower whole-body retention, indicating potentially lower risk for bone marrow toxicity [A31696].
Categories: Compounds used in a research, industrial, or household settingSynonyms: Lu-DOTATATE, [177]Lu-DOTA-TATEGepirone
go.drugbank.com/drugs/DB12184ApprovedGepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors. … It represents a novel class of antidepressants that selectively targets the 5HT<sub>1A</sub> receptors, thus possessing a more favorable side effects profile with comparable incidence of sexual dysfunction
Dalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalLMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. … Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.
Products: -liq 2500 Iu(anti-XA)/ml, FRAGMIN 2500 U.I/ML (ANTI-XA) VIAL DE 4 MLBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnLike semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class [A7866]. … These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting
Products: Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen, Ivor 3500 IE Anti-Xa/0,2 ml Injektionslösung in FertigspritzenFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalAzacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigationalDatopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx.
Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic Index